Paeonol protects against doxorubicin-induced cardiotoxicity by promoting Mfn2-mediated mitochondrial fusion through activating the PKCε-Stat3 pathway

INTRODUCTION: The anti-cancer medication doxorubicin (Dox) is largely restricted in clinical usage due to its significant cardiotoxicity. The only medication approved by the FDA for Dox-induced cardiotoxicity is dexrazoxane, while it may reduce the sensitivity of cancer cells to chemotherapy and is...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Mingge, Shi, Rui, Fu, Feng, Li, Man, De, Dema, Du, Yanyan, Li, Zongfang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173194/
https://www.ncbi.nlm.nih.gov/pubmed/35842187
http://dx.doi.org/10.1016/j.jare.2022.07.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10173194/
https://www.ncbi.nlm.nih.gov/pubmed/35842187
http://dx.doi.org/10.1016/j.jare.2022.07.002

Ejemplares similares